The use of natural mineral water “Donat” for functional constipation and constipation in comorbid patients

Мұқаба

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Constipation is a serious medical and social problem due to the widespread prevalence of this condition, decreased quality of life and social activity of patients. Functional constipation is a common gastroenterological pathology with no physiological, anatomical or iatrogenic origin can be identified.

The possibilities of natural mineral waters rich in magnesium sulfate in the treatment of constipation are considered. To date, three magnesium sulfate-rich natural mineral waters have been studied in randomized, double-blind, placebo-controlled clinical trials. A comparison of the effectiveness of the three mineral waters studied showed that Donat mineral water is the most effective. The results of a randomized clinical trial of Donat mineral water in the treatment of functional constipation, as well as the experience of its use in domestic studies that demonstrated the effectiveness and safety of Donat medicinal mineral water in pediatric practice and in adult patients with functional constipation are discussed in detail.

The characteristics of natural mineral water Donat allow to consider it as the first choice for the treatment of constipation in certain categories of comorbid patients. The rationale for the use of Donat mineral water for the treatment of constipation in patients with concomitant periodontal diseases and for the treatment of drug-induced constipation caused by the use of proton pump inhibitors is presented.

Толық мәтін

Рұқсат жабық

Авторлар туралы

Dmitry Trukhan

Omsk State Medical University

Хат алмасуға жауапты Автор.
Email: dmitry_trukhan@mail.ru
ORCID iD: 0000-0002-1597-1876

Dr. Sci. (Med.), Associate Professor, Professor at the Department of Outpatient Therapy and Internal Medicine

Ресей, Omsk

Maria Rozhkova

Omsk State Medical University

Email: dmitry_trukhan@mail.ru
ORCID iD: 0000-0002-7695-149X
Ресей, Omsk

Әдебиет тізімі

  1. Трухан Д.И., Деговцов Е.Н., Дрокина О.В. Пациент с синдромом запора на амбулаторно-поликлиническом приеме: актуальные аспекты дифференциальной диагностики и лечения. Медицинский совет. 2021;5:142–53. [Trukhan D.I., Degovtsov E.N., Drokina O.V. A patient with constipation syndrome at an outpatient clinic: current aspects of differential diagnosis and treatment. Medical advice. 2021;5:142–53. (In Russ.)]. doi: 10.21518/2079-701X-2021-5-142-153.
  2. Higgins P.D., Johanson J.F. Epidemiology of constipation in North America: A systematic review. Am J Gastroenterol. 2004;99:750–59. doi: 10.1111/j.1572-0241.2004.04114.x.
  3. Tack .J, Muller-Lissner S. Treatment of chronic constipation: Current pharmacologic approaches and future directions. Clin Gastroenterol Hepatol. 2009;7:502–8. 496. quiz. doi: 10.1016/j.cgh.2008.12.006.
  4. Ebling B., Gulic S., Jurcic D., et al. Demographic, anthropometric and socioeconomic characteristics of functional constipation in Eastern Croatia. Coll Antropol. 2014;38(2):539–46.
  5. Трухан Д.И., Филимонов С.Н. Диф-ференциальный диагноз основных гастроэнтерологических синдромов и симптомов. М.: Практическая медицина. 2016. 168 с. [Trukhan D.I., Filimonov S.N. Differential diagnosis of main gastroenterological syndromes and symptoms. M.: Practical medicine. 2016. 168 p. (In Russ.)].
  6. Парфенов А.И., Индейкина Л.Х., Беляева А. А., идр. Хронический запор. Методические рекомендации. Москва, 2016. 54 с. [Parfenov A.I., Indeikina L.Kh., Belyaeva A.A., etc. Chronic constipation. Guidelines. Moscow, 2016. 54 p. (In Russ.)].
  7. Лазебник Л.Б., Туркина С.В., Голованова Е.В. и др. Запоры у взрослых. Экспериментальная и клиническая гастроэнтерология. 2020; 175(3):10–33. [Lazebnik L.B., Turkina S.V., Golovanova E.V., et al. Constipation in adults. Experimental and clinical gastroenterology. 2020;175(3):10–33.doi: 10.31146/1682-8658-ecg-175-3-10-33.
  8. Тарасова Л.В., Трухан Д.И. Болезни кишечника. Клиника, диагностика и лечение. СПб.: СпецЛит, 2022. 222 с. [Tarasova L.V., Trukhan D.I. Intestinal diseases. Clinic, diagnosis and treatment. St. Petersburg: SpetsLit, 2022. 222 p. (In Russ.)].
  9. Irvine E.J., Ferrazzi S., Pare P., et al. Health-related quality of life in functional GI disorders: Focus on constipation and resource utilization. Am J Gastroenterol. 2002;97:1986–83. doi: 10.1111/j.1572-0241.2002.05843.x.
  10. Трухан Д.И., Филимонов С.Н. Диф-ференциальный диагноз основных симптомов и синдромов при заболеваниях желудочно-кишечного тракта: учебное пособие Новокузнецк: Полиграфист, 2022. 234 с. [Trukhan D.I., Filimonov S.N. Differential diagnosis of the main symptoms and syndromes in diseases of the gastrointestinal tract: textbook Novokuznetsk: Polygraphist, 2022. 234 p. (In Russ.)].
  11. Drossman D.A., Hasler W.L. Rome IV – Functional GI disorders: disorders of Gut-Brain interaction. Gastroenterology. 2016;150(6):1257–61. doi: 10.1053/j.gastro.2016.03.035.
  12. Lacy B.E., Patel N.K. Rome Criteria and a Diagnostic Approach to Irritable Bowel Syndrome. J Clin Med. 2017;6(11):iiE99. doi: 10.3390/jcm6110099.
  13. Шемеровский К.А., Селиверстов П.В., Бочкарёв М.В., Шайдуллина С.Р. Хронофизиологический механизм регулярности циркадианного ритма эвакуаторной функции кишечника. Экспериментальная и клиническая гастроэнтерология. 2019;5:150–53. [Shemerovsky K.A., Seliverstov P.V., Bochkarev M.V., Shaidullina S.R. Chronophysiological mechanism of regularity of the circadian rhythm of intestinal evacuation function. Experimental and clinical gastroenterology. 2019;5:150–53. (In Russ.)]. doi: 10.31146/1682-8658-ecg-165-5150-153.
  14. Шемеровский К.А., Селивёрстов П.В. Синдром брадиэнтерии вклинике внутренних болезней. Экспериментальная и клиническая гастроэнтерология. 2021;196(12):53–61. [Shemerovsky K.A., Seliverstov P.V. Bradyentery syndrome in the clinic of internal diseases. Experimental and clinical gastroenterology. 2021;196(12):53–61. (In Russ.)]. doi: 10.31146/1682-8658-ecg.
  15. Rao S.S.C., Lacy B.E., Emmanuel A., et al. Recognizing and Defining Occasional Constipation: Expert Consensus Recommendations. Am J Gastroenterol. 2022;117(11):1753–58. doi: 10.14309/ajg.0000000000001945.
  16. Honkura K., Tomata Y., Sugiyama K., et al. Defecation frequency and cardiovascular disease mortality in Japan: The Ohsaki cohort study. Atherosclerosis. 2016;246:251–56. doi: 10.1016/j.atherosclerosis.2016.01.007.
  17. Sundboll J., Szepligeti S.K., Adelborg K., et al. Constipation and risk of cardiovascular diseases: a Danish population-based matched cohort study. BMJ Open. 2020;10(9):e037080. doi: 10.1136/bmjopen-2020-037080.
  18. Sumida K., Molnar M.Z., Potukuchi P.K., et al. Constipation and risk of death and cardiovascular events. Atherosclerosis. 2019;281:114–20. doi: 10.1016/j.atherosclerosis.2018.12.021.
  19. Judkins C.P., Wang Y., Jelinic M., et al. Association of constipation with increased risk of hypertension and cardiovascular events in elderly Australian patients. Sci Rep. 2023;13(1):10943. doi: 10.1038/s41598-023-38068-y.
  20. Wald A., Scarpignato C., Mueller-Lissner S., et al. A multinational survey of prevalence and patterns of laxative use among adults with self-defined constipation. Aliment Pharmacol Ther. 2008;28:917–30. doi: 10.1111/j.1365-2036.2008.03806.x.
  21. Mugie S.M., Benninga M.A., Di Lorenzo C. Epidemiology of constipation in children and adults: A systematic review. Best Pract Res Clin Gastroenterol. 2011;25:3–18. doi: 10.1016/j.bpg.2010.12.010.
  22. Suares N.C., Ford A.C. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: Systematic review and meta-analysis. Am J Gastroenterol. 2011;106:1582–91. doi: 10.1038/ajg.2011.164.
  23. Zeitoun J.D., de Parades V. Chronic constipation in adults. Presse Med. 2013;42:1176–85. doi: 10.1016/j.lpm.2012.09.034.
  24. Sperber A.D., Bangdiwala S.I., Drossman D.A., et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology. 2021;160(1):99–114.e3. doi: 10.1053/j.gastro.2020.04.014.
  25. Кузнецова И.В., Успенская Ю.Б. Особенности заболеваний кишечника у женщин. Фарматека. 2013;18:72–8. [Kuznetsova I.V., Uspenskaya Yu.B. Features of intestinal diseases in women. Farmateka. 2013;18:72–8. (In Russ.)].
  26. Zhao Y.F., Ma X.Q., Wang R., et al. Epidemiology of functional constipation and comparison with constipation-predominant irritable bowel syndrome: the Systematic Investigation of Gastrointestinal Diseases in China (SILC). Aliment Pharmacol Ther. 2011;34(8):1020–29. doi: 10.1111/j.1365-2036.2011.04809.x.
  27. Трухан Д.И., Голошубина В.В., Белкина Л.В. Коморбидность в гинекологии: в фокусе – предменструальный синдром и синдром раздраженного кишечника. Клинический разбор в общей медицине. 2023;4(9):78–84. [Trukhan D.I., Goloshubina V.V., Belkina L.V. Comorbidity in gynecology: focus on premenstrual syndrome and irritable bowel syndrome. Clinical review for general practice. 2023;4(9):78–84. (In Russ.)]. doi: 10.47407/kr2023.4.9.00313.
  28. Liu L.W. Chronic constipation: current treatment options. Can J Gastroenterol. 2011;25 Suppl B(Suppl B):22B-28B.
  29. Olaru C., Diaconescu S., Trandafir L., et al. Some Risk Factors of Chronic Functional Constipation Identified in a Pediatric Population Sample from Romania. Gastroenterol Res Pract. 2016;2016:3989721. doi: 10.1155/2016/3989721.
  30. Velasco-Benitez C.A., Collazos-Saa L.I, Garcia-Perdomo H.A. A systematic review and meta-analysis in schoolchildren and adolescents with functional gastrointestinal disorders according to Rome IV criteria. Arq Gastroenterol. 2022;59(2):304–13. doi: 10.1590/S0004-2803.202202000-53.
  31. Murakami K., Sasaki S., Okubo H., et al. Association between dietary fiber, water and magnesium intake and functional constipation among young Japanese women. Eur J Clin Nutr. 2006;61:616–22. doi: 10.1038/sj.ejcn.1602573.
  32. Трухан Д.И., Филимонов С.Н. Заболевания кишечника: клиника, диагностика и лечение. Новокузнецк: ООО «Полиграфист». 2017. 223 с. [Trukhan D.I., Filimonov S.N. Intestinal diseases: clinical picture, diagnosis and treatment. Novokuznetsk: Polygraphist LLC, 2017. 223 p. (In Russ.)].
  33. Трухан Д.И. Дифференциальная диагностика запора. Справочник поликлинического врача. 2016;2:4–7. [Trukhan D.I. Differential diagnosis of constipation. Directory of a polyclinic doctor. 2016;2:4–7. (In Russ.)].
  34. Rollet M., Bohn T., Vahid F., On Behalf Of The Oriscav Working Group. Association between Dietary Factors and Constipation in Adults Living in Luxembourg and Taking Part in the ORISCAV-LUX 2 Survey. Nutrients. 2021;14(1):122. doi: 10.3390/nu14010122.
  35. Деговцов Е.Н., Трухан Д.И., Никоненко В.А., Косенок В.И. Синдром запора в хирургической практике: актуальные аспекты диагностики и лечения. Стационарозамещающие технологии: Амбулаторная хирургия. 2020;(1-2):46–56. [Degovtsov E.N., Trukhan D.I., Nikonenko V.A., Kosenok V.I. Constipation syndrome in surgical practice: current aspects of diagnosis and treatment. Hospital-replacing technologies: Outpatient surgery. 2020;(1-2):46–56. (In Russ.)]. doi: 10.21518/1995-1477-2020-1-2-46-56.
  36. Okawa Y., Fukudo S., Sanada H. Specific foods can reduce symptoms of irritable bowel syndrome and functional constipation: a review. Biopsychosoc Med. 2019 May 8;13:10. doi: 10.1186/s13030-019-0152-5.
  37. Schnabel L., Buscail C., Sabate J.M., et al. Association Between Ultra-Processed Food Consumption and Functional Gastrointestinal Disorders: Results From the French NutriNet-Santй Cohort. Am J Gastroenterol. 2018;113(8):1217–28. doi: 10.1038/s41395-018-0137-1.
  38. Vasseur P., Dugelay E., Benamouzig R., et al. Dietary Patterns, Ultra-processed Food, and the Risk of Inflammatory Bowel Diseases in the NutriNet-Santй Cohort. Inflamm Bowel Dis. 2021;27(1):65–73. doi: 10.1093/ibd/izaa018.
  39. Markland A.D., Palsson O., Goode P.S., et al. Association of low dietary intake of fiber and liquids with constipation: Evidence from the national health and nutrition examination survey. Am J Gastroenterol. 2013;108:796–803. doi: 10.1038/ajg.2013.73.
  40. Gilca-Blanariu G.E., Trifan A., Ciocoiu M., et al. Magnesium-A Potential Key Player in Inflammatory Bowel Diseases? Nutrients. 2022;14(9):1914. doi: 10.3390/nu14091914.
  41. Ивашкин В.Т., Шелыгин Ю.А., Маев И.В. и др. Диагностика и лечение запора у взрослых (Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(6):69–85. [Ivashkin V.T., Shelygin Yu.A., Maev I.V. and others. Diagnosis and treatment of constipation in adults (Clinical recommendations of the Russian Gastroenterological Association and the Association of Coloproctologists of Russia). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(6):69–85. (In Russ.)]. doi: 10.22416/1382-4376-2020-30-6-69-85.
  42. Bassotti G., Villanacci V., Corsetti M. Exploring Pharmacological Treatments for Chronic Idiopathic Constipation in Adults: A Look Back to the Future. J Clin Med. 2023;12(4):1702. doi: 10.3390/jcm12041702.
  43. Тарасова Л.В., Трухан Д.И. Болезни кишечника. Клиника, диагностика и лечение. СПб.: СпецЛит, 2013. 144 с. [Tarasova L.V., Trukhan D.I. Intestinal diseases. Clinic, diagnosis and treatment. St. Petersburg: SpetsLit, 2013. 144 p. (In Russ.)].
  44. Трухан Д.И. Функциональные гастроинтестинальные расстройства: перспективы использования лечебной минеральной воды. Медицинский совет. 2017;5:70–6. [Trukhan D.I. Functional gastrointestinal disorders: prospects for the use of medicinal mineral water. Medical advice. 2017;5:70–6. (In Russ.)]. doi: 10.21518/2079-701X-2017-5-70-76.
  45. Ефименко Н.В. Механизмы действия питьевых минеральных вод и их роль в курортной гастроэнтерологии. Курортная медицина. 2015;3:2–7. [Efimenko N.V. Mechanisms of action of drinking mineral waters and their role in resort gastroenterology. Kurortnaya meditsina. 2015;3:2–7. (In Russ.)].
  46. Fornai M., Colucci R., Antonioli L., et al. Effects of a bicarbonate-alkaline mineral water on digestive motility in experimental models of functional and inflammatory gastrointestinal disorders. Methods Find Exp Clin Pharmacol. 2008;30(4):261–69. doi: 10.1358/mf.2008.30.4.1159650.
  47. Fraioli A., Menunni G., Petraccia L., et al. Sulphate-bicarbonate mineral waters in the treatment of biliary and digestive tract diseases. Clin Ter. 2010;161(2):163–68.
  48. Dupont C., Campagne A., Constant F. Efficacy and safety of a magnesium sulfate-rich natural mineral water for patients with functional constipation. Clin Gastroenterol Hepatol. 2014;12(8):1280–87. doi: 10.1016/j.cgh.2013.12.005.
  49. Кручинина М.А., Пюрвеева К.В., Минушкин О.Н., Львова Н.В. Опыт применения минеральной воды «Донат Mg» в гастроэнтерологической практике. Медицинский совет. 2017;15:92–6. [Kruchinina M.A., Purveeva K.V., Minushkin O.N., Lvova N.V. Experience in using Donat Mg mineral water in gastroenterological practice. Medical advice. 2017;15:92–6. (In Russ.)]. doi: 10.21518/2079-701X-2017-15-92-96.
  50. Погорелова А.С. Роль минеральной воды «Донат Mg» в терапевтической практике. Медицинский совет. 2017;3:99–102. [Pogorelova A.S. The role of Donat Mg mineral water in therapeutic practice. Medical advice. 2017;3:99–102. (In Russ.)]. doi: 10.21518/2079-701X-2017-3-99-102.
  51. Куликов А.Г., Захарова И.Н., Творогова Т.М. и др. Применение магнийсодержащих минеральных вод при функциональных запорах у детей и подростков. Физиотерапия, бальнеология и реабилитация. 2018;5:272–78. [Kulikov A.G., Zakharova I.N., Tvorogova T.M. and others. The use of magnesium-containing mineral waters for functional constipation in children and adolescents. Physiotherapy, balneology and rehabilitation. 2018;5: 272–78. (In Russ.)]. doi: 10.17816/1681-3456-2018-17-5-272-278.
  52. Степурина Л.Л., Куликов А.Г., Захарова И.Н. и др. Применение магнийсодержащих минеральных вод при функциональных запорах у детей и подростков. Вестник физиотерапии и курортологии. 2019;4:101–6. [Stepurina L.L., Kulikov A.G., Zakharova I.N. and others. The use of magnesium-containing mineral waters for functional constipation in children and adolescents. Bulletin of physiotherapy and balneology. 2019;4:101–6. (In Russ.)].
  53. Мубаракшина О.А., Елизарова И.О., Черенкова О.В. Эффективность применения природной минеральной воды «DONAT» в комплексной терапии нарушений липидного и углеводного обменов. Фарматека. 2023;3:64–9. [Mubarakshina O.A., Elizarova I.O., Cherenkov O.V. The effectiveness of the use of natural mineral water «Donat» in the complex therapy of lipid and carbohydrate metabolism disorders. Farmateka. 2023;3:64–9. (In Russ.)]. doi: 10.18565/pharmateca.2023.3.64-68.
  54. Мубаракшина О.А., Батищева Г.А., Щербо-ва З.Р. Применение природной минеральной воды, богатой магнием и сульфатами, при функциональных запорах у взрослых и детей. Терапия. 2023;2: 158–64. [Mubarakshina O.A., Batishcheva G.A., Shcherbova Z.R. The use of natural mineral water, rich in magnesium and sulfates, for functional constipation in adults and children. Therapy. 2023;2: 158–64. (In Russ.)]. doi: 10.18565/therapy.2023.2.158-164.
  55. Dupont C, Hebert G. Magnesium Sulfate-Rich Natural Mineral Waters in the Treatment of Functional Constipation-A Review. Nutrients. 2020;12(7):2052. doi: 10.3390/nu12072052.
  56. Constant F., Morali A., Arnaud M.J., et al. Treatment of idiopathic constipation in infants: Comparative and randomized study of two mineral waters (60 cases) J Pediatr. Gastroenterol Nutr. 1999;28:551. doi: 10.1097/00005176-199905000-00052.
  57. Dupont C., Campagne A., Constant F. Efficacy and safety of a magnesium sulfate-rich natural mineral water for patients with functional constipation. Clin Gastroenterol Hepatol. 2014;12:1280–87. doi: 10.1016/j.cgh.2013.12.005.
  58. Dupont C., Constant F., Imbert A., et al. Time to treatment response of a magnesium- and sulphate-rich natural mineral water in functional constipation. Nutrition. 2019;65:167–72. doi: 10.1016/j.nut.2019.02.018.
  59. Naumann J., Sadaghiani C.D., Alt F., Huber R. Effects of Sulfate-Rich Mineral Water on Functional Constipation: A Double-Blind, Randomized, Placebo-Controlled Study. Complement Med Res 2016;23:356–63. doi: 10.1159/000449436.
  60. Bothe G., Coh A., Auinger A. Efficacy and safety of a natural mineral water rich in magnesium and sulphate for bowel function: A double-blind, randomized, placebo-controlled study. Eur. J. Nutr. 2015;56:491–99. doi: 10.1007/s00394-015-1094-8.
  61. Боте Г., Чох А., Ауингер А. Эффективность и безопасность природной минеральной воды, богатой магнием и сульфатами, для функции кишечника. Рандомизированное плацебо-контролируемое двойное слепое исследование. Медицинский совет. 2016;14:100–8. [Bothe G, Czoch A, Auinger A. Efficacy and safety of natural mineral water rich in magnesium and sulfates on intestinal function. Randomized, placebo-controlled, double-blind study. Medical advice. 2016;14:100–8. (In Russ.)]. doi: 10.21518/2079-701X-2016-14-100-108.
  62. Захарова И.Н., Творогова Т.М., Мумладзе Э.Б. и др. Лечебная минеральная вода: от прошлого к будущему. Медицинский совет. 2015;14:106–13. [Zakharova I.N., Tvorogova T.M., Mumladze E.B. et al. Medicinal mineral water: from the past to the future. Medical advice. 2015;14:106–13. (In Russ.)].
  63. Luft F.C., Zemel M.B., Sowers J.A., et al. Sodium bicarbonate and sodium chloride: effects on blood pressure and electrolyte homeostasis in normal and hypertensive man. J Hypertens. 1990;8(7):663–70. doi: 10.1097/00004872-199007000-00010.
  64. Petraccia L., Liberati G., Masciullo S.G., et al. Water, mineral waters and health. Clin Nutr. 2006;25(3):377–85. doi: 10.1016/j.clnu.2005.10.002.
  65. Quattrini S., Pampaloni B., Brandi M.L. Natural mineral waters: chemical characteristics and health effects. Clin Cases Miner Bone Metab. 2016;13(3):173–80. doi: 10.11138/ccmbm/2016.13.3.173.
  66. Drossman D.A. The Functional Gastrointestinal Disorders and the Rome III Process. Gastroenterology 2006; 130 (5): 1377–90. doi: 10.1053/j.gastro.2006.03.008.
  67. Коровина Н.А., Захарова И.Н., Гаврюшова Л.П. и др. Применение минеральной воды «Донат Mg» при соматической патологии у детей. Пособие для практикующих врачей-педиатров. М., 2005. 60 с. [Korovina N.A., Zakharova I.N., Gavryushova L.P. and others. The use of Donat Mg mineral water for somatic pathology in children. A manual for practicing pediatricians. M., 2005. 60 p. (In Russ.)].
  68. Захарова И.Н., Елезова Л.И., Степурина Л.Л. и др. Применение природной минеральной воды, обогащенной магнием, при лечении запоров у детей. Вопросы современной педиатрии, 2013;12(3):56–63. [Zakharova I.N., Elezova L.I., Stepurina L.L. and others. The use of natural mineral water enriched with magnesium in the treatment of constipation in children. Issues of modern pediatrics, 2013;12(3):56–63. (In Russ.)].
  69. Эфендиева М.Т., Бадшиева В.А., Русенко Н.И. Магнийсодержащие минеральные воды в лечении больных с кардиальными проявлениями гастроэзофагеальной рефлюксной болезнью. Вопросы курортологии, физиотерапии и лечебной физкультуры, 2006;6:31–3. [Efendieva M.T., Badshieva V.A., Rusenko N.I. Magnesium-containing mineral waters in the treatment of patients with cardiac manifestations of gastroesophageal reflux disease. Issues of balneology, physiotherapy and physical therapy, 2006;6:31–3. (In Russ.)].
  70. Захарова И.Н., Куликов А.Г., Османов И.М. и др. Функциональный запор у детей: современные критерии диагностики и подходы к лечению. Педиатрия. Приложение к журналу Consilium Medicum. 2018;2:51–7. [Zakharova I.N., Kulikov A.G., Osmanov I.M. and others. Functional constipation in children: modern diagnostic criteria and approaches to treatment. Pediatrics. Consilium Medicum. 2018;2:51–7. (In Russ.)]. doi: 10.26442/2413-8460_2018.2.51-57.
  71. Трухан Д.И., Рожкова М.Ю., Голошубина В.В. Хронический функциональный запор у пациентов молодого и среднего возраста: деликатная проблема – деликатное решение. Фарматека. 2023;30(1-2):44–53. [Trukhan D.I., Rozhkova M.Yu., Goloshubina V.V. Chronic functional constipation in young and middle age patients: delicate problem – delicate decision. Farmateka. 2023;30(1-2):44–53. (In Russ.)]. doi: 10.18565/pharmateca.2023.1-2.44-53.
  72. Фролков В.К. Новые представления о механизмах лечебно-профилактического действия питьевых минеральных вод. Клиническая медицина и фармакология. 2015;4:34–6. [Frolkov V.K. New ideas about the mechanisms of therapeutic and prophylactic action of drinking mineral waters. Clinical medicine and pharmacology. 2015;4:34–6. (In Russ.)].
  73. Фролков В.К. Механизмы влияния «Донат Mg» на обмен веществ и заболевания желудочно-кишечного тракта. [Frolkov V.K. Mechanisms of influence of “Donat Mg” on metabolism and diseases of the gastrointestinal tract. (In Russ.)]. URL: http://donatmg.ru/issledov/klinika/2009/09/29/ klinika_13.html
  74. Фролков В.К. Влияние «Донат Mg» на резистентность слизистой желудка при действии стрессорных факторов. [Frolkov V.K. The effect of Donat Mg on the resistance of the gastric mucosa under the influence of stress factors. (In Russ.)]. URL: http://donatmg.ru/issledov/klinika/ 2009/09/29/klinika_12.html
  75. Балаболкин М.И. Изучение влияния «Донат Mg» на состояние больных инсулиннезависимым сахарным диабетом: информационно-методическое пособие. М., 2003. 12 с. [Balabolkin M.I. Study of the effect of “Donat Mg” on the condition of patients with non-insulin-dependent diabetes mellitus: information and methodological manual. M., 2003. 12 p. (In Russ.)].
  76. Balta M.G., Papathanasiou E., Blix I.J., Van Dyke T.E. Host Modulation and Treatment of Periodontal Disease. J Dent Res. 2021;100(8):798–809. doi: 10.1177/0022034521995157.
  77. Williams R.C., Offenbacher S. Periodontal medicine: The emergence of a new branch of periodontology. Periodontology 20002000,23, 9–12. doi: 10.1034/j.1600-0757.2000.2230101.x.
  78. Трухан Д.И., Трухан Л.Ю. Пародонтит и сердечно-сосудистые заболевания: параллельно или в одной связке? Consilium Medicum. 2015;5:73–9. [Trukhan D.I., Trukhan L.Yu. Periodontitis and cardiovascular diseases: in parallel or in one bundle? Consilium Medicum. 2015;5:73–9. (In Russ.)].
  79. Трухан Д.И., Трухан Л.Ю. Некоторые аспекты коморбидности пародонтита и сердечно-сосудистых заболеваний. Медицинский совет. 2015;17:12–6. [Trukhan D.I., Trukhan L.Yu. Some aspects of comorbidity of periodontitis and cardiovascular diseases. Medical advice. 2015;17:12–6. (In Russ.)].
  80. Трухан Д.И., Трухан Л.Ю. Взаимоотношения болезней пародонта и сердечно-сосудистых заболеваний. Международный журнал сердца и сосудистых заболеваний. 2016;11:15–24. [Trukhan D.I., Trukhan L.Yu. Relationship between periodontal and cardiovascular diseases. International Heart and Vascular Disease Journal. 2016;11:15–24. (In Russ.)]. doi: 10.24412/2311-1623-2016-11-15-24.
  81. Трухан Д.И., Трухан Л.Ю., Иванова Д.С. Коморбидность заболеваний сердечно-сосудистой системы и болезней органов пищеварения с изменениями органов и тканей полости рта. Клинический разбор в общей медицине. 2021;3:6–17. [Trukhan D.I., Trukhan L.Yu, Ivanova D.S. Comorbidity of diseases of the cardiovascular system and diseases of the digestive organs with changes in organs and tissue of the oral cavity. Clinical review for general practice. 2021;3:6–17. (In Russ.)]. doi: 10.47407/kr2021.2.3.00044.
  82. Трухан Д.И., Сулимов А.Ф., Трухан Л.Ю. Коморбидность артериальной гипертензии и пародонтита: стоматологическая гипертензия. Клинический разбор в общей медицине. 2023;4(6):62–8. [Trukhan D.I., Sulimov A.F., Trukhan L. Yu. Comorbidity of arterial hypertension and periodontitis: dental hypertension. Clinical review for general practice. 2023;4(6):62–8. (In Russ.)]. doi: 10.47407/kr2023.4.5.00273.
  83. Трухан Д.И., Сулимов А.Ф., Трухан Л.Ю. Ассоциация артериальной гипертензии и патологии пародонта: обзор новых данных. Фарматека. 2023;30(9–10):40–51. [Trukhan D.I., Sulimov A.F., Trukhan L.Yu. Association of arterial hypertension and periodontal disease: a review of new data. Farmateka. 2023;30(9-10):40–51. (In Russ.)]. doi: 10.18565/pharmateca.2023.9-10.40-51.
  84. Трухан Д.И., Сулимов А.Ф., Трухан Л.Ю. Взаимосвязь преэклампсии и патологии пародонта. Клинический разбор в общей медицине. 2023;4(9):115–21. [Trukhan D.I., Sulimov A.F., Trukhan L. Yu. The relationship between preeclampsia and periodontal pathology. Clinical review for general practice. 2023;4(9):115–21. (In Russ.)]. doi: 10.47407/kr2023.4.9.00317.
  85. Campos J.R., Martins C.C., Faria S.F.S., et al. Association between components of metabolic syndrome and periodontitis: a systematic review and meta-analysis. Clin Oral Investig. 2022;26(9):5557-5574. doi: 10.1007/s00784-022-04583-x.
  86. Prasad V.G., Abraham P. Management of chronic constipation in patients with diabetes mellitus. Indian J Gastroenterol. 2017;36(1):11–22. doi: 10.1007/s12664-016-0724-2.
  87. Wei L., Ji L., Miao Y., et al. Constipation in DM are associated with both poor glycemic control and diabetic complications: Current status and future directions.Biomed Pharmacother. 2023;165:115202. doi: 10.1016/j.biopha.2023.115202.
  88. Concepcion Zavaleta M.J., Gonzales Yovera J.G., Moreno Marreros D.M., et al. Diabetic gastroenteropathy: An underdiagnosed complication. World J Diabetes. 2021;12(6):794–809. doi: 10.4239/wjd.v12.i6.794.
  89. Kikuchi K., Tanaka H., Gima M., et al. Abnormalities of magnesium (Mg) metabolism and therapeutic significance of Mg administration in patients with metabolic syndrome, type 2 diabetes, heart failure and chronic hemodialysis Clin Calcium. 2012;22(8):1217–26.
  90. Varela-Lуpez A., Giampieri F., Bullon P., et al. A Systematic Review on the Implication of Minerals in the Onset, Severity and Treatment of Periodontal Disease. Molecules. 2016;21(9):1183. doi: 10.3390/molecules21091183.
  91. Meisel P., Pink C., Nauck M., et al. Magnesium/Calcium Ratio in Serum Predicts Periodontitis and Tooth Loss in a 5-Year Follow-up. JDR Clin Trans Res. 2016;1(3):266–74. doi: 10.1177/2380084416663458.
  92. Li X.Y., Wen M.Z., Liu H., et al. Dietary magnesium intake is protective in patients with periodontitis. Front Nutr. 2022;9:976518. doi: 10.3389/fnut.2022.976518.
  93. Belluci M.M., de Molon R.S., Rossa C.Jr., et al. Severe magnesium deficiency compromises systemic bone mineral density and aggravates inflammatory bone resorption. J Nutr Biochem. 2020;77:108301. doi: 10.1016/j.jnutbio.2019.108301.
  94. Pushparani D.S., Anandan S.N., Theagarayan P. Serum zinc and magnesium concentrations in type 2 diabetes mellitus with periodontitis. J Indian Soc Periodontol. 2014;18(2):187–93. doi: 10.4103/0972-124X.131322.
  95. Shetty A., Bhandary R., Thomas B., Ramesh A. A Comparative Evaluation of Serum Magnesium in Diabetes Mellitus Type 2 Patients with and without Periodontitis - A Clinico-biochemical Study. J Clin Diagn Res. 2016;10(12):ZC59-ZC61. doi: 10.7860/JCDR/2016/21063.9078.
  96. Meisel P., Schwahn C., Luedemann J., et al. Magnesium deficiency is associated with periodontal disease. J Dent Res. 2005;84(10):937–41. doi: 10.1177/154405910508401012.
  97. Watson S., Woodside J.V., Winning L., et al. Associations between self-reported periodontal disease and nutrient intakes and nutrient-based dietary patterns in the UK Biobank. J Clin Periodontol. 2022;49(5):428–38. doi: 10.1111/jcpe.13604.
  98. Hildebolt C.F. Effect of vitamin D and calcium on periodontitis. J Periodontol. 2005;76(9):1576–87. doi: 10.1902/jop.2005.76.9.1576.
  99. O’Connor J.P., Milledge K.L., O’Leary F., et al. Poor dietary intake of nutrients and food groups are associated with increased risk of periodontal disease among community-dwelling older adults: a systematic literature review. Nutr Rev. 2020;78(2):175–88. doi: 10.1093/nutrit/nuz035.
  100. Nishida M., Grossi S.G., Dunford R.G., et al. Calcium and the risk for periodontal disease. J Periodontol. 2000;71(7):1057–66. doi: 10.1902/jop.2000.71.7.1057.
  101. Ramesh A., Mahajan K., Thomas B., et al. Alveolar bone mass in pre- and postmenopausal women with serum calcium as a marker: a comparative study. Indian J Dent Res. 2011;22(6):878. doi: 10.4103/0970-9290.94667.
  102. Agrawal A.A., Kolte A.P., Kolte R.A., et al. Evaluation and comparison of serum vitamin D and calcium levels in periodontally healthy, chronic gingivitis and chronic periodontitis in patients with and without diabetes mellitus – a cross-sectional study. Acta Odontol Scand. 2019;77(8):592–99. doi: 10.1080/00016357.2019.1623910.
  103. Nascimento G.G., Leite F.R.M., GonzalezChica D.A., et al. Dietary vitamin D and calcium and periodontitis: A population-based study. Front Nutr. 2022;9:1016763. doi: 10.3389/fnut.2022.1016763.
  104. Garcia M.N., Hildebolt C.F., Miley D.D., et al. One-year effects of vitamin D and calcium supplementation on chronic periodontitis. J Periodontol. 2011;82(1):25–32. doi: 10.1902/jop.2010.100207.
  105. Chandel S., Khan M.A., Singh N., et al. The effect of sodiumbicarbonateoral rinse on salivary pH and oral microflora: A prospective cohort study. Natl J Maxillofac Surg. 2017;8(2):106–9. doi: 10.4103/njms.NJMS_36_17.
  106. Madeswaran S., Jayachandran S. Sodium bicarbonate: A review and its uses in dentistry. Indian J Dent Res. 2018;29(5):672–77. doi: 10.4103/ijdr.IJDR_30_17.
  107. Taschieri S., Tumedei M., Francetti L., et al. Efficacy of 67% sodium bicarbonate toothpaste for plaque and gingivitis control: a systematic review and meta-analysis. J Evid Based Dent Pract. 2022;22(2):101709. doi: 10.1016/j.jebdp.2022.101709.
  108. Пугина Е.А. Оптимизация регуляции углеводного и липидного обмена с применением магнийсодержащих минеральных вод. Автореферат диcс. кандидата медицинских наук. Москва, 2006. 24 с. [Pugina E.A. Optimization of the regulation of carbohydrate and lipid metabolism using magnesium-containing mineral waters. Abstract of the dissertation of a candidate of medical sciences. Moscow, 2006. 24 p. (In Russ.)].
  109. Karasawa Y., Nozawa K., Nakajima A. Potential drug-induced constipation: A retrospective study using a Japanese claims database. JGH Open. 2024;8(2):e13036. doi: 10.1002/jgh3.13036.
  110. Лазебник Л.Б., Ткаченко Е.И., Абдулганиева Д.И. и др. VI Национальные рекомендации по диагностике и лечению кислотозависимых и ассоциированных с Helicobacter pylori заболеваний (VI Московские соглашения). Экспериментальная и клиническая гастроэнтерология. 2017;(2):3–21. [Lazebnik L.B., Tkachenko E.I., Abdulganiyeva D.I., et al VI National guidelines for the diagnosis and treatment of acid-related and Helicobacter pylori-associated diseases (VI Moscow agreement). Experimental and Clinical Gastroenterology. 2017;(2):3–21. (In Russ.)].
  111. Novotny M., Klimova B., Valis M. PPI Long Term Use: Risk of Neurological Adverse Events? Front Neurol. 2019;9:1142. doi: 10.3389/fneur.2018.01142.
  112. Chinzon D., Domingues G., Tosetto N., Perrotti M. Safety of long-termprotonpumpinhibitors: facts and myths. Arq Gastroenterol. 2022;59(2): 219–25. doi: 10.1590/S0004-2803. 202202000-40.
  113. Thurber K.M., Otto A.O., Stricker S.L. Protonpumpinhibitors: Understanding the associated risks and benefits of long-term use. Am J Health Syst Pharm. 2023;80(8):487–94. doi: 10.1093/ajhp/zxad009.
  114. Maideen N.M.P. Adverse Effects Associated with Long-Term Use of Proton Pump Inhibitors. Chonnam Med J. 2023;59(2):115–27. doi: 10.4068/cmj.2023.59.2.115.
  115. Трухан Д.И. Лекарственная безопасность: в фокусе долгосрочная терапия ингибиторами протонной помпы. Вероятные побочные эффекты. Клинический разбор в общей медицине. 2024;5(1):48–56. [Trukhan D.I. Drug safety: focus on long-term therapy with proton pump inhibitors. Probable side effects. Clinical analysis in general medicine. 2024;5(1):48–56. (In Russ.)]. doi: 10.47407/kr2023.5.1.00360.
  116. Yibirin M., De Oliveira D., Valera R., et al. Adverse effects associated with proton pump inhibitor use. Cureus 2021;13:e12759 doi: 10.7759/cureus.12759.
  117. Maezawa M., Inoue M., Satake R., et al. Effect of acid suppressant medications on the laxative action of magnesium preparations in patients with opioid-induced constipation: A pharmacovigilance analysis of the FDA Adverse Event Reporting System. Pharmazie. 2023;78(11):245–50. doi: 10.1691/ph.2023.3624.
  118. Saha M., Shil B.C., Uddin M.K., et al. Bowel Habit Pattern of Patients with Self-Reported Constipation at Out Patient Department in North East Part of Bangladesh. Mymensingh Med J. 2022;31(4):998–1004.
  119. Ueki T., Nagai K., Mizukami Y., et al. Cross-sectional study on relationship between constipation and medication in consideration of sleep disorder. Yakugaku Zasshi. 2011;131(8):1225–32. doi: 10.1248/yakushi.131.1225.
  120. Gommers L.M.M., Hoenderop J.G.J., de Baaij J.H.F. Mechanisms ofprotonpumpinhibitor-induced hypomagnesemia. Acta Physiol (Oxf). 2022;235(4):e13846. doi: 10.1111/apha.13846.
  121. Luk C.P., Parsons R., Lee Y.P., Hughes J.D. Proton pump inhibitor-associated hypomagnesemia: what do FDA data tell us? Ann Pharmacother 2013;47:773–80. doi: 10.1345/aph.1R556.
  122. Park C.H., Kim E.H., Roh Y.H., et al. The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysis. PLoS One 2014;9:e112558. doi: 10.1371/journal.pone.0112558.
  123. Cheungpasitporn W., Thongprayoon C., Kittanamongkolchai W., et al. Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies. Ren Fail. 2015;37:1237–41. doi: 10.3109/0886022X.2015.1057800.
  124. Srinutta T., Chewcharat A., Takkavatakarn K., et al. Proton pump inhibitors and hypomagnesemia: a meta-analysis of observational studies. Medicine (Baltimore) 2019;98:e17788. doi: 10.1097/MD.0000000000017788.
  125. Rooney M.R., Bell E.J., Alonso A., et al. ProtonPumpInhibitorUse, Hypomagnesemia and Risk of Cardiovascular Diseases: The Atherosclerosis Risk in Communities (ARIC) Study. J Clin Gastroenterol. 2021;55(8):677–83. doi: 10.1097/MCG.0000000000001420.
  126. Markovits N., Loebstein R., Halkin H., et al. The association of proton pump inhibitors and hypomagnesemia in the community setting. J Clin Pharmacol. 2014;54(8):889–95. doi: 10.1002/jcph.316.
  127. Recart D.A., Ferraris A., Petriglieri C.I., et al. Prevalence and risk factors of long-term proton pump inhibitors-associated hypomagnesemia: a cross-sectional study in hospitalized patients. Intern Emerg Med. 2021;16(3):711–17. doi: 10.1007/s11739-020-02501-1.
  128. Makunts T., Cohen I.V., Awdishu L., Abagyan R. Analysis of postmarketing safety data for proton-pump inhibitors reveals increased propensity for renal injury, electrolyte abnormalities, and nephrolithiasis. Sci Rep 2019;9:2282 doi: 10.1038/s41598-019-39335-7.
  129. Liamis G., Milionis H.J., Elisaf M. A review of drug-inducedhypocalcemia. J Bone Miner Metab. 2009;27(6):635–42. doi: 10.1007/s00774-009-0119-x.
  130. Morris C., Pillans P. Protonpumpinhibitor-associated hypomagnesaemia andhypocalcaemia. Aust Prescr. 2017;40(2):79-80. doi: 10.18773/austprescr.2017.019.
  131. Tagboto S. Severe Electrolyte Disturbances Due toProtonPumpInhibitor Therapy: An Underrecognized Problem with Potentially Severe Sequelae. Am J Case Rep. 2022;23:e936893. doi: 10.12659/AJCR.936893.
  132. Al Ali H.S., Jabbar A.S., Neamah N.F., Ibrahim N.K. Long-Term Use of Omeprazole: Effect on Haematological and Biochemical Parameters. Acta Med Indones. 2022;54(4):585–94.
  133. Liamis G., Milionis H., Elisaf M. A review of drug-induced hyponatremia. Am J Kidney Dis. 2008;52(1):144–53. doi: 10.1053/j.ajkd.2008.03.004.
  134. Qureshi A.S., Quadri M.A., Javed B. Unusual Neurological Manifestation of Proton Pump Inhibitor: A Case Report of Acute Disseminated Encephalomyelitis and Severe Hyponatremia After Brief Use of Proton Pump Inhibitor. Cureus. 2021;13(6):e15571. doi: 10.7759/cureus.15571.
  135. Paul L.P., Martin J., Buon M., et al. Nouvel effet indesirable frequent des inhibiteurs de la pompe à protons chez le sujet age : l’hyponatremie moderee. Therapie. 2014;69(2):157–62. doi: 10.2515/therapie/2014019.
  136. Goto M., Sakai M. Proton-pump inhibitor use andhyponatremia. Nihon Ronen Igakkai Zasshi. 2023;60(2):153–57. doi: 10.3143/geriatrics.60.153.
  137. Falhammar H., Lindh J.D., Calissendorff J., et al. Associations of proton pump inhibitors and hospitalization due to hyponatremia: A population-based case-control study. Eur J Intern Med. 2019;59:65–9. doi: 10.1016/j.ejim.2018.08.012.
  138. Issa I., Skov J., Falhammar H., et al. Time-dependent association between omeprazole and esomeprazole and hospitalization due to hyponatremia. Eur J Clin Pharmacol. 2023;79(1):71–7. doi: 10.1007/s00228-022-03423-x.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2024